Overview

Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)

Status:
Terminated
Trial end date:
2018-05-18
Target enrollment:
Participant gender:
Summary
This is a Phase I/II multicenter, first-in-human open-label, dose escalation study to evaluate the safety, tolerability, and anti-tumor activity of intratumoral (IT)/intralesional (IL) injections of MK-4621 (RGT100) in adult participants with selected advanced or recurrent tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Rigontec GMBH